Imagene AI is a significant player in the specialized "expert agent" segment of the AI ecosystem. While not building general-purpose agents, they have developed an orchestration layer for biological and clinical data. Their Cross-Modality Intelligence Engine acts as an autonomous analytical agent for pathologists and biopharma researchers, performing the labor-intensive task of biomarker identification and trial matching that previously required human-led lab processes.
In the broader agent stack, Imagene represents the application of foundation models to narrow, high-stakes domains. They are championing the use of multimodal models—combining vision and text—to drive automated reasoning in precision medicine. For builders in the AI space, Imagene is a case study in how to wrap a specialized model in a SaaS layer (CanvOI) to create a tool that moves from passive analysis to active clinical decision support.
Imagene AI is an infrastructure provider for the next era of oncology. Founded in 2020 and headquartered in Miami, the company specializes in multimodal foundation models that interpret biological and clinical data. In the current medical paradigm, identifying the specific genetic mutations of a tumor—essential for targeted therapy—often takes weeks of lab work. Imagene is attempting to collapse this timeframe. Their software analyzes digital pathology slides to detect molecular biomarkers in real-time, effectively using light and pixels to infer what previously required chemical sequencing.
The core of the company's offering is the Cross-Modality Intelligence Engine. This system is trained on diverse datasets, including histopathology (tissue images), gene expression, and clinical records. By training models that understand the relationship between how a tissue looks under a microscope and its underlying genetic profile, Imagene allows clinicians to bypass lengthy waiting periods. The company refers to this as "Living Intelligence," emphasizing that their models are not static diagnostic tests but adaptive systems that evolve as more data is processed.
Their primary product is the OI Suite (Oncology Intelligence Suite), a SaaS platform designed for biopharma and clinical teams. For drug developers, the engine is used to optimize clinical trial design by identifying patients who are most likely to respond to a specific treatment based on their digital tissue profile. This capability is particularly useful for small clinical cohorts where traditional screening might be too slow or expensive.
In 2025, Imagene AI closed a $23 million Series B funding round, bringing their total capital to $45 million. The round was led by Oracle Chairman and CTO Larry Ellison, which has significant implications for the company's technical architecture. Imagene now uses Oracle’s cloud infrastructure to run its compute-heavy models, ensuring they meet the high security and performance requirements of hospital systems. Oracle Health EVP Seema Verma and CEO Safra Catz have both publicly endorsed the technology, signaling a deep partnership that could see Imagene's models integrated directly into Oracle’s health record systems.
Dean Bitan, CEO and co-founder, leads a team that includes co-founders Jonathan Zalach (Chief Data Scientist) and Shahar Porat (CTO). The company maintains a presence in both Miami and Tel Aviv, drawing on Israel’s concentrated healthcare data and AI talent. Their current partnerships include major diagnostic and clinical institutions such as Tempus, Sectra, and the Sheba Medical Center. These collaborations allow Imagene to test their models in live clinical environments, moving AI diagnostics from research curiosities into practical, everyday pathology workflows.
A transformative SaaS platform for biomarker discovery and clinical decision support.
Imagene AI is hiring.